Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis: early-phase trial registry
120 of 317 indexed Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #24 of 28,707 conditions by registered trial count.
317 US clinical trials · 120 currently recruiting · #24 of 28,707 conditions by registered trial count
Multiple Sclerosis: 317 US clinical trials tracked, 120 recruiting.
Multiple Sclerosis is the subject of 317 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 41 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 13 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis
OPEN 120 | RECR 38% | LATE 41 | EARLY 74 | RANK #24 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Myeloma (38% recruiting · 441 trials)
Multiple Sclerosis lists 120 open slots (38% of 317 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis recruits in line with its size-band peers.
120 of 317 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 13 of 317 trials (4.1%). 142 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 316 trials that report a genuine target (sentinel values excluded). 181 of those (57.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis research is mostly interventional.
231 interventional and 86 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
317 total, page 2 of 7
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
University of Alabama at Birmingham
NCT03759522
Functional Balance Intervention in Multiple Sclerosis
University of Illinois at Chicago
NCT06341023
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06220201
Obesity and Pediatric Multiple Sclerosis
University of Virginia
NCT04593082
Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
University of Washington
NCT06809192
Home Based Infusions for Ocrelizumab
University of Colorado, Denver
NCT04650321
A Study of the MIND Diet for Persons With Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
NCT06992115
Intestinal Immunity in Neurologic Disease
Yale University
NCT06329453
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Northwestern University
NCT07207148
Non-invasive BCI-controlled Assistive Devices
University of Texas at Austin
NCT05183152
Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.
University of Illinois at Chicago
NCT05516537
Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection
University of Kansas Medical Center
NCT06434571
This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
Washington University School of Medicine
NCT07115017
Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension
University of Massachusetts, Boston
NCT06554340
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
Kessler Foundation
NCT06197685
Home Based Functional Balance Intervention for Multiple Sclerosis
University of Illinois at Chicago
NCT07355387
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
University of Kansas Medical Center
NCT06428006
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Kyverna Therapeutics
NCT07403188
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
University of Colorado, Denver
NCT06641271
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Genentech
NCT07008378
An Individualized-health eLibrary App for People With Multiple Sclerosis
University of Illinois at Urbana-Champaign
NCT05124600
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
Massachusetts General Hospital
NCT04699747
Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS
University of Colorado, Boulder
NCT05500963
Blood Flow Restriction And Veterans With MS
VA Office of Research and Development
NCT05433103
Glucose Consumption in MS Using [F-18]FDG-PET
Brigham and Women's Hospital
NCT07087106
Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)
University of Southern California
NCT06515782
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
MGH Institute of Health Professions
NCT06136728
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Johns Hopkins University
NCT06170970
Central Vein Sign in Multiple Sclerosis Extension Study
The Cleveland Clinic
NCT07424027
Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis
University of St. Augustine for Health Sciences
NCT06981013
Promotion of Exercise Through Physical Therapy for Multiple Sclerosis: A Pilot Study
University of Michigan
NCT06933160
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Northwestern University
NCT07225361
Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community
Kessler Foundation
NCT06608797
Remote Evaluation of MIND Diet
University of Illinois at Urbana-Champaign
NCT06450977
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Shirley Ryan AbilityLab
NCT06516458
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X
NCT07477639
Nomad P-KAFO Study
Shirley Ryan AbilityLab
NCT05644522
Eccentric Exercise and Fatigue in Multiple Sclerosis
Hunter College of City University of New York
NCT06505421
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
ImStem Biotechnology
NCT04956744
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
State University of New York at Buffalo
NCT06463743
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
University of Chicago
NCT06171152
Effect of Cooling on Balance Performance in Multiple Sclerosis
Hunter College of City University of New York
NCT06094855
Assessment of Synaptic Density in MS
Brigham and Women's Hospital
NCT04634994
Noninvasive Vagal Nerve Stimulation
NYU Langone Health
NCT06816004
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
National Institute of Neurological Disorders and Stroke (NINDS)
NCT02784210
User-friendliness of a Portable Driving Simulator
University of Kansas Medical Center
NCT03969927
Effectiveness of Task Specific Home Exercise Program
New York Presbyterian Brooklyn Methodist Hospital
NCT06486116
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
The Methodist Hospital Research Institute
NCT06072703
Smoldering Inflammation in MS
Washington University School of Medicine
NCT06591429
Dry Needling in Multiple Sclerosis
University of Kansas Medical Center
NCT06394310
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 33 |
| Phase 3 | 24 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis page
317 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis condition card totals 317 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.